Jump to content
Wikipedia The Free Encyclopedia

AOP-208

From Wikipedia, the free encyclopedia

Pharmaceutical compound
AOP-208
Clinical data
Other namesAOP208; LB-208; LB208
Routes of
administration 		Oral [1] [2]
Drug class Serotonin 5-HT1B receptor antagonist

AOP-208, also known as LB-208, is a selective serotonin 5-HT1B receptor antagonist which is under development for the treatment of lymphoma, solid tumors, acute myeloid leukemia, and myelodysplastic syndromes.[1] [3] [2] It is taken orally.[1] [2] The drug is being developed by AOP Orphan Pharmaceuticals AG and Leukos Biotech.[1] [3] As of October 2024, it is in phase 1 clinical trials for lymphoma and solid tumors and is in the preclinical research stage of development for acute myeloid leukemia and myelodysplastic syndromes.[1] [3] The chemical structure of AOP-208 does not yet appear to have been disclosed.[1]

References

[edit ]
  1. 1 2 3 4 5 6 "AOP 208". AdisInsight. 8 October 2024. Retrieved 24 January 2026.
  2. 1 2 3 Rojas Laimito K, Molina Lores G, Nuciforo P, Smiljkovic D, Unger M, Krejcy K, et al. (2025). "1024eTiP LB-208/AOP208 a first-in-class HTR1B antagonist: First-in-human, dose finding phase I study for the evaluation of safety, pharmacokinetics, pharmacodynamics, and anti-tumor activity in adult patients with relapsed or refractory solid tumors or lymphoma" . Annals of Oncology. 36: S625. doi:10.1016/j.annonc.2025年08月15日93 . Retrieved 24 January 2026.
  3. 1 2 3 "Delving into the Latest Updates on AOP-208 with Synapse". Synapse. 19 July 2025. Retrieved 24 January 2026.
[edit ]
Stub icon

This antineoplastic or immunomodulatory drug article is a stub. You can help Wikipedia by adding missing information.

AltStyle によって変換されたページ (->オリジナル) /